Population pharmacokinetic modeling of the Qishe pill in three major traditional Chinese medicine-defined constitutional types of healthy Chinese subjects: study protocol for a randomized controlled trial

Yue-li Sun, Ting Hou, Shu-fen Liu, Zhong-liang Zhang, Ning Zhang, Min Yao, Long Yang, Qi Shi, Xue-jun Cui, Yong-jun Wang, Yue-li Sun, Ting Hou, Shu-fen Liu, Zhong-liang Zhang, Ning Zhang, Min Yao, Long Yang, Qi Shi, Xue-jun Cui, Yong-jun Wang

Abstract

Background: High incidences of neck pain morbidity are challenging in various situations for populations based on their demographic, physiological and pathological characteristics. Chinese proprietary herbal medicines, as Complementary and Alternative Medicine (CAM) products, are usually developed from well-established and long-standing recipes formulated as tablets or capsules. However, good quantification and strict standardization are still needed for implementation of individualized therapies. The Qishe pill was developed and has been used clinically since 2009. The Qishe pill's personalized medicine should be documented and administered to various patients according to the ancient TCM system, a classification of personalized constitution types, established to determine predisposition and prognosis to diseases as well as therapy and life-style administration. Therefore, we describe the population pharmacokinetic profile of the Qishe pill and compare its metabolic rate in the three major constitution types (Qi-Deficiency, Yin-Deficiency and Blood-Stasis) to address major challenges to individualized standardized TCM.

Methods/design: Healthy subjects (N = 108) selected based on constitutional types will be assessed, and standardized pharmacokinetic protocol will be used for assessing demographic, physiological, and pathological data. Laboratory biomarkers will be evaluated and blood samples collected for pharmacokinetics(PK) analysis and second-generation gene sequencing. In single-dose administrations, subjects in each constitutional type cohort (N = 36) will be randomly divided into three groups to receive different Qishe pill doses (3.75, 7.5 and 15 grams). Multiomics, including next generation sequencing, metabolomics, and proteomics, will complement the Qishe pill's multilevel assessment, with cytochrome P450 genes as targets. In a comparison with the general population, a systematic population pharmacokinetic (PopPK) model for the Qishe pill will be established and verified.

Trial registration: This study is registered at ClinicalTrials.gov, NCT02294448 .15 November 2014.

Figures

Figure 1
Figure 1
Patient flowchart detailing the process, including screening, allocation, and analysis.
Figure 2
Figure 2
Architecture and basic elements of the population pharmacokinetic (PopPK) research based on medical informatics and data management.
Figure 3
Figure 3
Mean plasma concentration-time curves of seven components after oral administration of the Qishe pill at medium and high dosages (n = 4).

References

    1. Aker PD, Gross AR, Goldsmith CH, Peloso P. Conservative management of mechanical neck pain: systematic overview and meta-analysis. BMJ. 1996;313(7068):1291–6. doi: 10.1136/bmj.313.7068.1291.
    1. Cui X, Trinh K, Wang YJ. Chinese herbal medicine for chronic neck pain due to cervical degenerative disc disease. Cochrane Database Syst Rev. 2010; (1), CD006556
    1. Wang Q. Classification of the nine basic TCM constitutional type and based expression and diagnosis. J Beijing University Tradit Chin Med. 2005(04); 1-8.
    1. Wang Q, Zhu YB. Epidemiological investigation of constitutional types of Chinese medicine in general population: Base on 21,948 epidemiological investigation data of nine provinces in China. ZhongHuaZhong Yi Yao ZaZhi. 2009;24:7–12.
    1. Wang Q, Zhu YB, Xue HS. Primary compiling of constitution in Chinese Medicine questionnaire. ZhongGuo Lin Chuang Kang Fu. 2006;10:12–4.
    1. Zhu YB, Wang Q, Xue HS, Origasa H. Preliminary assessment on performance of constitution in Chinese medicine questionnaire. ZhongGuo Lin Chuang Kang Fu. 2006;10:15–7.
    1. Zhu YB, Wang Q, Origasa H. Evaluation on reliability and validity of the constitution in Chinese medicine questionnaire (CCMQ) ZhongGuo Xing Wei Yi XueKeXue. 2007;16:651–4.
    1. Mei L, Zhang N, Wang YJ, Shi Q. Purification process research of major compound in Qishe Pill as Astragalus. Acta Chin Med Pharmacol. 2006;34:14–6.
    1. Zhang YQ, Liu XH, Zhang N, Liu M. Quality standard research of Qishe Pill. Lishizhen Med Mater Med Res. 2008;19:977–9.
    1. Liu M, Zhang N, Wang YJ, Zhang YQ, Zhou CJ. Technology research of Qishe Pill, a new medicine for cervical spondylosis. Lishizhen Med Mater Med Res. 2010;21:176–9.
    1. Ge JR, Wang HM, Meng CX, Tong PJ. Effects of Qishe Pill, a compound traditional Chinese herbal medicine, on cervical radiculopathy: a randomized controlled trial for Phase III. Chin J New Drugs Clin. 2014;7:56–8.
    1. Hsu H-Y. 1986 Oriental MateriaMedica. Long Beach, CA: Oriental Healing Arts Institute; 1986.
    1. Maurer K. U.S. Department of Health, Education, and Welfare. Basic data on arthritis knee, hip and sacroiliac joints in adults ages 25–74 years: United States, 1971–1975. Health Stat. 1979;11:1–31.
    1. Mäkelä M, Heliövaara M, Sievers K, Impivaara O, Knekt P, Aromaa A. Prevalence, determinants, and consequences of chronic neck pain in Finland. Am J Epidemiol. 1991;134:1356–67.
    1. Bovim G, Schrader H, Sand T. Neck pain in the general population. Spine (Phila Pa 1976) 1994;19:1307–9. doi: 10.1097/00007632-199406000-00001.
    1. Van der Donk J, Schouten JS, Passchier J, van Romunde LK, Valkenburg HA. The associations of neck pain with radiological abnormalities of the cervical spine and personality traits in a general population. J Rheumatol. 1991;18:1884–9.
    1. Choo V. WHO reassesses appropriate body-mass index for Asian populations. Lancet. 2002;360:235. doi: 10.1016/S0140-6736(02)09512-0.
    1. FDA/CDER. Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers; July, 2005, .
    1. EMEA. Strategies to identify and mitigate risks for first-in-human clinical trialswith investigational medicinal products; Sept. 2009, .
    1. Zhang ZL, Li Q, Li QF, Du SM, Zhou YQ, Lv CM, et al. Simultaneous determination of nineteen major components in Qishe Pill by ultra-high-performance liquid chromatography–tandem mass spectrometry. Acta Pharmaceutica Sinica B (2014);
    1. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1980;8:553–71. doi: 10.1007/BF01060053.
    1. Sheiner BL, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experi- mental pharmacokinetic data. J Pharmacokinet Biopharm. 1981;9:635–51. doi: 10.1007/BF01061030.
    1. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm. 1983;11:303–19. doi: 10.1007/BF01061870.
    1. Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, et al. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol. 2008;66:629–39.
    1. Qingmao Y. An 80-cases clinical observation of two conservative therapy of traditional Chinese and western medicine to cervical spondylotic radiculopathy. Chinese Foreign Health Abs. 2010;18:223–5.
    1. Bin-Chia Wu D, Tsai YW, Wen YW. Bayesian cost-effectiveness analysis for censored data-an application to antiplatelet therapy. J Med Econ. 2012;15:434–43. doi: 10.3111/13696998.2011.653510.
    1. Okada K, Tanaka H, Temporin K, Okamoto M, Kuroda Y, Moritomo H, et al. Methylcobalamin increases Erk1/2 and Akt activities through the methylation cycle and promotes nerve regeneration in a rat sciatic nerve injury model. Exp Neurol. 2010;222:191–203. doi: 10.1016/j.expneurol.2009.12.017.
    1. Zhang WJ, Hufnagl P, Binder BR. Anti-inflammatory activity of astragaloside IV is mediated by inhibition of NF-qB activation and adhesion molecule expression. Thromb Haemost. 2003;90:904–14.
    1. Chen SL, Jiang GH. Security and pharmacilogical effects of Szechuan Lovage Rhizome extract. J Chengdu UnivTradit Chin Med. 2009;32:63–5.
    1. Sun X, Yu XJ, Qiu MF. Clinical research progress of the pharmacology of ovientvine. J China’s Integrated Tradit Chin Western Med Surg. 2005;11:363–4.
    1. Li X, Yu QH. Anti-inflammatory effects of Calculus BovisArtifactus: apilot study. J Shengyang Pharm Univ. 2000;17:431–3.
    1. Liang QQ, Zhang M, Zhou Q, Shi Q, Wang YJ. Muscone protects vertebral end-plate degeneration by anti-inflammatory property. ClinOrthop Relat Res. 2010;468:1600–10. doi: 10.1007/s11999-009-1079-0.
    1. Du SM, Pan YF, Zhang N. Simultaneous determination with HPLC internal standard method for nine kinds ingredients in Qishe Pill. Chin Tradit Pat Med. 2012;7:1271–5.
    1. Li Q, Du SM, Li QF, Zhang ZL, Zhang N. Effects of Qishe Pill on cervical radiculopathy rat model with Qi-deficiency and Blood-stasis syndrome. Pharmacol Clin. 2013;4:118–21.
    1. Du SM, Li Q, Li QF, Zhang ZL, Zhang N. Invivo tissue distribution research of ingredients in Qishe Pill. Chin J Exp Formulas Chin Med. 2013;19:171–6.
    1. Wang D, Song Y, Li SL, Bian YY, Guan J, Li P. Simultaneous analysis of seven astragalosides in Radix Astragali and related preparations by liquid chromatography coupled with electrospray ionization time-of-flight mass spectrometry. J Sep Sci. 2006;29:2012–22. doi: 10.1002/jssc.200500486.
    1. Yu QT, Qi LW, Li P, Yi L, Zhao J, Bi ZM. Determination of seventeen main flavonoids and saponins in the medicinal plant Huang-qi (Radix Astragali) by HPLC-DAD-ELSD. J Sep Sci. 2007;30:1292–9. doi: 10.1002/jssc.200600422.
    1. Huang X, Ren P, Wen AD, Wang LL, Zhang L, Gao F. Pharmacokinetics of traditional Chinese syndrome and recipe: a hypothesis and its verification (I) World J Gastroenterol. 2000;6:384–91.
    1. Tian Y, Yang ZF, Li Y, Qiao Y, Yang J, Jia YY, et al. Pharmacokinetic comparisons of hydroxysafflower yellow A in normal and blood stasis syn- drome rats. J Ethnopharmacol. 2010;129:1–4. doi: 10.1016/j.jep.2010.02.023.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj